Innate Pharma announces key leadership and corporate governance changes to support next stage of development
Preliminary safety and clinical activity results for IPH4102 to be presented at the Third World Congress of Cutaneous Lymphomas
Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Safety data for Lirilumab in combination with Nivolumab or Ipilimumab to be presented at the ESMO 2016 Congress
Seventh data and Safety Monitoring Board Meeting of the EffiKIR trial recommends continuation without modification
First half of 2016: building momentum through clinical development and new partnerships
Innate Pharma to host European analyst and investor event in London on July 13th 2016
ASCO 2016: Phase I study protocol investigating IPH4102 in cutaneous T-cell lymphomas
Outcome of Annual General meeting of june 2, 2016
Number of shares and voting rights of Innate Pharma as at may 30, 2016
